CONTENTS

Certificate i
Declaration ii
Preface iii
Acknowledgement iv
Abbreviations v
List of tables vi
List of figures vii
I Introduction 1
1.1 Classification
1.2 Aetiology of type 2 diabetes
1.3 Epidemiology
1.4 Pathophysiology
1.5 Clinical signs and symptoms
1.6 Complications
1.7 Diagnosis
1.8 Management
1.9 Peroxisome proliferators activated receptors (PPARS)
1.10 Thiazolidinediones
1.11 Chemical structure of thiazolidinediones
1.12 Pharmacokinetics
1.13 Clinical Pharmacology
   1.13.1 Thiazolidinediones and glycaemic control
   1.13.2 Other vascular effects of thiazolidinediones
   1.13.3 Effects on the lipid profile
   1.13.4 Lowering blood pressure
   1.13.5 Additional anti-atherogenic effects
Scope of the study 19
Literature survey 20

II Materials and methods 31
2.1 Study design
2.2 Biochemical studies 33
   2.2.1 Estimation of blood sugar
   2.2.2 Estimation of blood urea
   2.2.3 Estimation of serum creatinine
   2.2.4 Estimation of uric acid
   2.2.5 Estimation of insulin
   2.2.6 Estimation of glycosylated haemoglobin
   2.2.7 Estimation of free fatty acids
   2.2.8 Estimation of cholesterol
   2.2.9 Estimation of triglycerides
   2.2.10 Estimation of HDL - cholesterol
   2.2.11 Estimation of HDL - cholesterol
2.2.12 Estimation of HDL - cholesterol
2.2.13 Estimation of alkaline phosphatase
2.2.14 Estimation of aspartate transaminase
2.2.15 Estimation of alanine transaminase
2.2.16 Estimation of microalbumin
2.2.17 Qualitative analysis of urine

2.3 Haematological studies
2.3.1 Determination of total erythrocyte count by haemocytometry
2.3.2 Estimation of total leukocyte count
2.3.3 Determination of differential WBC count.
2.3.4 Estimation of erythrocyte sedimentation rate

2.4 Immunological studies
2.4.1 Determination of serum IgG
2.4.2 Determination of serum IgM
2.4.3 Determination of serum IgA
2.4.4 Determination of serum IgE
2.4.5 Estimation of C -reactive protein
2.4.6 Estimation of plasma cortisol
2.4.7 Estimation of plasminogen activator inhibitor -1 (PAI-1)
2.4.8 Estimation of plasma fibrinogen
2.4.9 Estimation of complement
2.4.10 Estimation of ceruloplasmin
2.4.11 Estimation of serum alpha 1 anti-trypsin
2.4.12 Estimation of serum haptoglobin
2.4.13 Estimation of interleukin -6
2.4.14 Estimation of tumour necrosis factor - α
2.4.15 Estimation of adiponectin

III Results
3.1 Evaluation of biochemical, haematological and immunological alterations in type 2 diabetes mellitus
3.1.1 Biochemical alterations in type 2 diabetic patients
3.1.2 Haematological alterations in type 2 diabetic patients
3.1.3 Alterations in the levels of various immunological parameters in type 2 diabetic patients

3.2 Effect of rosiglitazone in type 2 diabetic patients
3.2.1 Effect of rosiglitazone on biochemical parameters in type 2 diabetic patients
3.2.2 Effect of rosiglitazone on haematological parameters in type 2 diabetic patients
3.2.3 Effect of rosiglitazone on immunological parameters in type 2 diabetic patients

3.3 Effect of pioglitazone in type 2 diabetic patients
3.3.1 Effect of pioglitazone on biochemical parameters in type 2 diabetic patients
3.3.2 Effect of pioglitazone on haematological parameters in type 2 diabetic patients
3.3.3 Effect of pioglitazone on immunological parameters in type 2 diabetic patients

3.4 Comparison between the effect of rosiglitazone and pioglitazone in type 2 diabetic patients
3.4.1 Effect of rosiglitazone and pioglitazone on biochemical parameters in type 2 diabetic patients
3.4.2 Effect of rosiglitazone and pioglitazone on haematological parameters in type 2 diabetic patients
3.4.3 Effect of rosiglitazone and pioglitazone on immunological parameters in type 2 diabetic patients

IV Discussion

5.1 Evaluation of biochemical, haematological and immunological alterations in type 2 diabetics
  5.1.1 Evaluation of biochemical alterations in type 2 diabetics
  5.1.2 Evaluation of haematological alterations in type 2 diabetics
  5.1.3 Evaluation of immunological alterations in type 2 diabetics
5.2 Effect of rosiglitazone in type 2 diabetic patients
  5.2.1 Effect of rosiglitazone on biochemical parameters in type 2 diabetic patients
  5.2.2 Effect of rosiglitazone on hematological parameters in type 2 diabetic patients
  5.2.3 Effect of rosiglitazone on immunological parameters in type 2 diabetic patients
5.3 Effect of pioglitazone in type 2 diabetic patients
  5.3.1 Effect of pioglitazone on biochemical parameters in type 2 diabetic patients
  5.3.2 Effect of pioglitazone on hematological parameters in type 2 diabetic patients
  5.3.3 Effect of pioglitazone on immunological parameters in type 2 diabetic patients
5.4 Comparative study of rosiglitazone and pioglitazone in type 2 diabetes mellitus
  5.4.1 Comparative study of rosiglitazone and pioglitazone on biochemical parameters in type 2 diabetic patients
  5.4.2 Comparative study of rosiglitazone and pioglitazone on hematological parameters in type 2 diabetic patients
  5.4.3 Comparative study of rosiglitazone and pioglitazone on immunological parameters in type 2 diabetic patients

V Summary and Conclusions

References

List of publications